Navigation Links
Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis

at the company’s upcoming R&D day on June 20, 2007 at 2 pm (CET) and provide then further details about preclinical and clinical results.


About the combined phase I/IIa study

The multi-centre, randomized, placebo-controlled and double-blind study included 48 male and female patients suffering from moderate to severe plaque psoriasis. An initial part of the study with a total of 24 participants evaluated the safety and tolerability of ascending doses of the vaccine (100 ?g, 300 ?g). It was followed by a second study part with a total of 24 participants that was designed to evaluate exploratory efficacy of the highest previously tested vaccine dose (i.e. 300 ?g) compared to placebo. Patients of this latter group were randomized 1:1 into the vaccine-treated and the placebo group and either received 5 subcutaneous injections of 300 ?g CYT007-TNFQb or placebo at weeks 0, 2, 4, 8 and 12. Upon entry into the study and then every two weeks up to week 16, the patients’ disease severity was determined by the Psoriasis Area and Severity Index (PASI).

About psoriasis and CYT007-TNFQb

Psoriasis is a common chronic skin disorder that affects 1-3% of the world’s population (National Psoriasis Foundation, USA). Plaque psoriasis is the most common form of the disease (>80% of cases) and it is characterized by inflamed red patches of skin topped with silvery white scales. While there are a number of medications that may help to control the symptoms of psoriasis, there is as yet no cure. Psoriasis is considered to be linked to an overactive immune system where inflammatory cytokines play an essential role. The inflammatory cytokine tumor necrosis factor alpha (TNF-?) has been described as a key molecule in the pathogenesis of psoriasis. Consequently, recently approved anti-TNF-? biologics have proven effective; however, they have to be administered frequently and at high doses and are therefore associated
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ... body composition, including reductions in body fat content ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. ... a premier and affordable laser tattoo removal experience with the ... Brandeis, focus is in providing high quality cosmetic services with ... all patients. " Southern California ... regret and patients seeking removal for those unwanted tattoos," said ...
(Date:1/14/2014)... NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ... disciplines and even across industries. NineSigma ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... Male high school athletes more likely to drink and fight ... News) -- When it comes to teaching healthy behaviors, boys, ... thought. , New research suggests that for teenage boys, participation ... and binge drinking. , Girls, on the other hand, ...
... Study finds medication works as well in certain people, ... -- People suffering from blocked renal arteries fare just ... by having the narrowed artery opened and a stent ... chronic kidney disease -- people with severe hypertension -- ...
... ... employment and networking portal for people with disabilities and renews its commitment to leading the ... ... recently passed a milestone, the one year anniversary of the launch on November 7, 2008 ...
... Announces VSO Support For Lung Cancer Legislation , ... all veterans today on Veterans Day and announces the ... veterans on lung cancer -- the leading cause of ... ) , LCA also announces that major ...
... Near 9% Unemployment Leaves More Idaho Families Struggling with ... , BOISE, Idaho, Nov. 11 As Idaho,s jobless ... the over 67,300 unemployed Idahoans finding themselves without employer benefits. ... is calling on Idaho,s Congressional delegation to set politics aside ...
... Nov. 11 Accelify is proud to announce the addition of ... of Development in the State of Florida and will also join ... Accelify, Sandra served for eight years as a member of the ... During her time in the Florida legislature, she personally sponsored ...
Cached Medicine News:Health News:Boys' Team Sports May Encourage Bad Behavior 2Health News:Boys' Team Sports May Encourage Bad Behavior 3Health News:Surgery Not Always Best for Narrowed Kidney Arteries 2Health News:Surgery Not Always Best for Narrowed Kidney Arteries 3Health News:GettingHired.com Recognizes First Year Anniversary, Renews Commitment to Helping Lead the Effort to Reduce Employment Participation Gap for People with Disabilities 2Health News:GettingHired.com Recognizes First Year Anniversary, Renews Commitment to Helping Lead the Effort to Reduce Employment Participation Gap for People with Disabilities 3Health News:Lung Cancer Alliance Salutes Veterans 2Health News:Idaho's Rising Jobless Rate Fuels State's Growing Health Care Woes 2Health News:Accelify Announces the Addition of Sandra L. Murman to its National Board of Advisors 2Health News:Accelify Announces the Addition of Sandra L. Murman to its National Board of Advisors 3
... TC-PLUS Solution tricompartmental total knee prosthesis stems ... arthroplasty. State-of-the-art design and manufacturing technologies have ... biomechanical function as well as a favorable ... insert to keep wear to a minimum. ...
... The TC-PLUS Solution tricompartmental total knee prosthesis ... knee arthroplasty. State-of-the-art design and manufacturing technologies ... optimum biomechanical function as well as a ... tibial insert to keep wear to a ...
... Knee System is a long term, quality ... Available in both posterior stabilized and anatomically ... System provides the flexibility needed to address ... ease of identification keeps the user in ...
... a long term, quality solution based on ... posterior stabilized and anatomically correct cruciate retaining ... flexibility needed to address patients' needs. In ... keeps the user in mind and promotes ...
Medicine Products: